A Phase 1 interventional study of BI 10773 Placebo and BI 10773 in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-04.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 85th largest by enrollment, is the only one that started in 2007, is one of 24 in phase 1, and was the 30th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 81st largest by enrollment of the 96 interventional ones that give a count, is one of 4 that started in 2007, is one of 19 in phase 1, and was the 77th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics of BI 10773 after multiple dosing, including dose proportionality and assessment of steady state.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
concomitant diseases other than type 2 diabetes, hyperlipidaemia and medically treated hypertension, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
multiple doses as tablet
Drug: BI 10773 Placebo · Drug: BI 10773
multiple doses as tablet
Drug: BI 10773 · Drug: BI 10773 Placebo
multiple doses as tablet
Drug: BI 10773 Placebo · Drug: BI 10773
multiple doses as tablet
Drug: BI 10773 Placebo · Drug: BI 10773
po taken fasting with 240 mL water
po taken fasting with 240 mL water
po taken fasting with 240 mL water
po taken fasting with 240 mL water
po taken fasting with 240 mL water
po taken fasting with 240 mL water
po taken fasting with 240 mL water
po taken fasting with 240 mL water
Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests
Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).
Time frame: day 1 to day 21
Percentage of Participants With Clinically Relevant Findings in Electrocardiogram (ECG) Results
Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results
Time frame: day 1 to day 21
Micturition Frequency
Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.
Time frame: Baseline and Day 9
Assessment of Tolerability by Investigator
Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.
Time frame: day 21
Concentration of the Analyte in Plasma
Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval (AUC)
AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Time to Maximum Concentration of the Analyte in Plasma
Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1.-0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Terminal Rate Constant in Plasma
Terminal rate constant in plasma after first dose and at steady-state
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Half-life and Mean Residence Time of the Analyte in Plasma
Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Apparent Volume of Distribution During the Terminal Phase
Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Amount of Analyte Eliminated in Urine
Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)
Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9
Fraction of Analyte Excreted Unchanged in Urine
Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100. Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.
Time frame: 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 hours (h) after dose on day 1 and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24, 24-36, 36-48 and 48-72 hours (h) after dose on day 9
Apparent and Renal Clearance of the Analyte in Plasma
Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state. Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state. Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Peak Trough Fluctuation
Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Linearity Index
The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Accumulation Ratios
Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state. Accumulation ratio for the respective doses were calculated using below mentioned equations: RA,Cmax = Cmax,ss/Cmax RA,AUC= AUCtau,ss/AUCtau
Time frame: -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h and 48h after dose on day 1. -0:05 before dose and 0:10,0:20,0:30,0:40,1h,1:30h,2h,3h,4h,6h,8h,12h,16h,24h,30h,36h, 48h,60h and 72h after dose on day 9.
Change From Baseline to Day 8 in Urinary Glucose Excretion
Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.
Time frame: -2-0 hours(h) before drug administration and 0-2, 2-4, 4-6, 6-8, 8-12,12-16 and 16-24 h after drug administration on day -2 and day 8
Mean Daily Glucose
Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.
Time frame: 0:00, 2:00, 5:00, 7:00, 10:00, 12:00,13:30 and 24:00 hours(h) after drug administration on day -2 and -0.05, 2:30, 5:00, 7:00, 10:00, 12.00, 13:30 and 24:00 hours (h) after drug administration on day 8
Fasting Plasma Glucose
Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.
Time frame: -0:30 (Pre dose samples)
Serum Insulin
Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5. AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.
Time frame: 0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8
Serum Insulin
Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12. Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) \& Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)
Time frame: 0.0h, 2h, 5h, 7h, 10h, 12h on day -2 & day 8
This Phase I trial was randomised, double-blind, and placebo-controlled within dose groups. It was to be performed in 48 female and male patients with type 2 diabetes in 4 sequential groups of 12 patients each. Within each dose group, 9 patients were to receive active drug and 3 were to receive placebo.
| Milestone | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Started | 12 | 9 | 9 | 9 | 9 |
| Completed | 11 | 9 | 8 | 9 | 9 |
| Not completed | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 |
Percentage of participants with clinically relevant findings in physical examination, vital signs and clinical laboratory tests. Relevant findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).
| percentage of participants | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Cardiac disorders | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Investigations: Hepatic enzyme increased | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of participants with clinically relevant findings in electrocardiogram (ECG) results
| percentage of participants | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Clinically relevant | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Clinically irrelevant | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
Micturition frequency is reported as change from pre-treatment to day 9 during the day, the night and total. Baseline is the mean of days 8-3 before drug administration.
| frequency of micturition | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Micturition day frequency | 4.1 ± 1.8 | 2.6 ± 2.1 | 5.0 ± 1.6 | 3.9 ± 1.5 | 4.4 ± 2.1 |
| Micturition night frequency | 0.3 ± 1.6 | 0.2 ± 1.2 | 0.5 ± 0.5 | 0.6 ± 1.6 | 0.7 ± 0.9 |
| Micturition total frequency | 4.5 ± 2.1 | 2.8 ± 2.6 | 5.5 ± 1.5 | 4.4 ± 2.4 | 5.1 ± 2.2 |
Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.
| percentage of participants | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Good | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 |
| Satisfactory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Not satisfactory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Bad | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 |
Maximum concentration of the analyte in plasma (Cmax) after first dose, Maximum, minimum (Cmin) and average (Cavg) concentration of the analyte in plasma at steady-state, Concentration of analyte in plasma at 24 h after administration of the 8th dose (at steady-state) (C24,8)
| nmol/L | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Cmax after first dose | 61.3 ± 20.5 | 240 ± 21.2 | 592 ± 23.7 | 2670 ± 26.1 |
| Cmax at steady-state (N=9,8,9,8) | 66.6 ± 26.7 | 272 ± 30.1 | 622 ± 17.4 | 2700 ± 20.9 |
| Cmin at steady-state (N=9,8,9,8) | 4.41 ± 36.9 | 23.5 ± 31.5 | 47.1 ± 35.3 | 243 ± 32.0 |
| Cavg at steady-state (N=9,8,9,8) | 19.2 ± 24.3 | 83.5 ± 17.4 | 204 ± 21.5 | 922 ± 28.7 |
| C24,8 (N=9,8,9,8) | 4.55 ± 36.8 | 23.8 ± 31.7 | 47.2 ± 35.2 | 249 ± 27.6 |
AUC0-∞: from 0 extrapolated to infinity after first dose AUCtau,1: over a uniform dosing interval tau after first dose AUCtau,ss: over a uniform dosing interval tau at steady-state AUCs were computed using the linear up/log down algorithm. If an analyte concentration was equal to or higher than the preceding concentration, the linear trapezoidal method was to be used. If the analyte concentration was smaller than the preceding concentration, the logarithmic method was to be used.
| nmol*h/L | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| AUC0-∞ after first dose | 468 ± 19.6 | 1890 ± 14.7 | 4780 ± 23.7 | 23300 ± 19.4 |
| AUC0-24 after first dose | 397 ± 17.6 | 1620 ± 13.5 | 4200 ± 23.6 | 19700 ± 17.6 |
| AUC0-tau at steady state (N=9,8,9,8) | 460 ± 24.3 | 2000 ± 17.4 | 4890 ± 21.5 | 22100 ± 28.7 |
Time from last dosing to maximum concentration of the analyte in plasma (tmax) after first dose and at steady-state
| h | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| tmax after first dose | 1.50 ± 27.5 | 1.50 ± 18.2 | 1.50 ± 38.5 | 3.00 ± 77.8 |
| tmax at steady-state (N=9,8,9,8) | 1.50 ± 27.4 | 1.50 ± 24.3 | 2.00 ± 62.6 | 1.50 ± 62.3 |
Terminal rate constant in plasma after first dose and at steady-state
| 1/h | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Terminal rate after first dose | 0.0618 ± 22.4 | 0.0586 ± 11.5 | 0.0654 ± 19.9 | 0.0527 ± 26.8 |
| Terminal rate at steady-state (N=9,8,9,8) | 0.0686 ± 18.5 | 0.0491 ± 17.5 | 0.0658 ± 18.8 | 0.0409 ± 48.4 |
Terminal half life of the analyte in plasma (t1/2) and mean residence time of the analyte in the body after single oral administration (MRTpo) after first dose and at steady-state.
| h | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| t1/2 after first dose | 11.2 ± 22.4 | 11.8 ± 11.5 | 10.6 ± 19.9 | 13.2 ± 26.8 |
| t1/2 at steady state (N=9,8,9,8) | 10.1 ± 18.5 | 14.1 ± 17.5 | 10.5 ± 18.8 | 17.0 ± 48.4 |
| MRT po after first dose | 12.2 ± 12.4 | 12.1 ± 19.1 | 11.0 ± 13.5 | 12.7 ± 19.7 |
| MRT po at steady-state (9,8,9,8) | 10.7 ± 14.2 | 13.5 ± 22.7 | 11.2 ± 13.7 | 14.6 ± 20.6 |
Apparent volume of distribution during the terminal phase (Vz/F) after first dose and at steady state. Apparent volume is defined as CL/F divided by the terminal rate constant in plasma (either after first dose or at steady-state).
| L | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Vz/F after first dose | 192 ± 27.2 | 200 ± 19.5 | 177 ± 27.9 | 181 ± 35.1 |
| Vz/F at steady state (N=9,8,9,8) | 176 ± 25.0 | 225 ± 25.9 | 172 ± 21.7 | 245 ± 56.7 |
Amount of analyte that is eliminated in urine after first dose and at steady state from the time interval 0 to 24 h (Ae0-24) and 0 to 48 h (Ae0-48)
| nmol | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Ae0-48 after first dose | 706 ± 24.7 | 2570 ± 42.2 | 5250 ± 52.0 | 18500 ± 32.7 |
| Ae0-48 at steady-state (N=9,8,8,9) | 941 ± 32.1 | 4530 ± 23.5 | 8450 ± 42.7 | 22400 ± 145 |
| Ae0-24 after first dose | 613 ± 26.9 | 2250 ± 42.7 | 4770 ± 54.6 | 16600 ± 34.3 |
| Ae0-24 at steady-state (N=9,8,8,9) | 820 ± 33.9 | 4040 ± 26.7 | 7520 ± 43.6 | 19300 ± 153 |
Fraction of analyte excreted unchanged in urine in the time interval 0 to 12 h (fe0-12) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-12 by the Dose and multiply it with 100. Fraction of analyte excreted unchanged in urine in the time interval 0 to 24 h (fe0-24) after first dose and at steady-state. The fraction excreted was calculated by dividing Ae0-24 by the Dose and multiply it with 100.
| percent of analyte | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| fe0-12 after first dose | 8.50 ± 31.9 | 8.43 ± 39.8 | 6.30 ± 78.2 | 6.17 ± 37.6 |
| fe0-12 at steady-state (N=9,8,8,9) | 10.6 ± 47.0 | 14.7 ± 26.5 | 9.22 ± 54.0 | 6.68 ± 154 |
| fe0-24 after first dose | 11.1 ± 26.9 | 10.1 ± 42.7 | 7.38 ± 73.0 | 7.48 ± 34.3 |
| fe0-24 at steady-state (N=9,8,8,9) | 14.8 ± 33.9 | 18.2 ± 26.7 | 11.4 ± 53.6 | 8.71 ± 153 |
Apparent clearance of the analyte in plasma (CL/F) after first dose and at steady-state, Renal clearance of the analyte in plasma after extravascular administration (CLR) after first dose and at steady-state. Apparent clearance after first dose is defined as the dose divided by AUC0-∞; apparent clearance at steady-state is defined as the dose divided by AUC0-tau at steady-state. Renal clearance CLR(0-t) is defined as Ae0-t divided by AUC0-t.
| mL/min | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| CL/F after first dose | 198 ± 19.6 | 195 ± 14.7 | 193 ± 23.7 | 159 ± 19.4 |
| CL/F at steady-state (N=9,8,9,8) | 201 ± 24.3 | 184 ± 17.4 | 189 ± 21.5 | 167 ± 28.7 |
| CLR (0-48h) after first dose | 26.7 ± 42.9 | 23.5 ± 33.0 | 18.8 ± 53.1 | 13.9 ± 44.1 |
| CLR (0-24h) at steady-state (N=9,8,8,9) | 29.7 ± 52.0 | 33.6 ± 24.9 | 21.7 ± 47.1 | 22.2 ± 83.3 |
Peak trough fluctuation (PTF) is defined as the difference between Cmax and Cmin divided by Cavg and multiplied with 100% at steady-state
| PTF(%) of Empagliflozin | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Peak Trough Fluctuation | 323 ± 20.6 | 294 ± 28.4 | 281 ± 26.4 | 265 ± 31.9 |
The linearity index is defined as AUC0-tau divided by AUC0-∞ both at steady state.
| Fraction | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Linearity Index | 0.983 ± 8.42 | 1.05 ± 2.39 | 1.02 ± 11.4 | 0.962 ± 19.7 |
Accumulation ratio based on Cmax (RA,Cmax) and Accumulated ratio based on AUC0-tau (RA,AUC) at steady-state. Accumulation ratio for the respective doses were calculated using below mentioned equations: RA,Cmax = Cmax,ss/Cmax RA,AUC= AUCtau,ss/AUCtau
| Ratio | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|
| Accumulation ratio based on Cmax | 1.09 ± 27.0 | 1.13 ± 20.9 | 1.05 ± 22.3 | 0.972 ± 36.8 |
| Accumulated ratio based on AUC0-tau | 1.16 ± 8.39 | 1.23 ± 6.17 | 1.16 ± 11.9 | 1.12 ± 20.7 |
Change from baseline to day 8 in urinary glucose excretion. Baseline is defined as Day -2.
| mg | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Change From Baseline to Day 8 in Urinary Glucose Excretion | -3254.43 ± 8250.43 | 34638.37 ± 16226.22 | 78709.87 ± 53463.52 | 74030.40 ± 35378.01 | 88040.32 ± 20265.87 |
Change from baseline to Day 8 in mean daily glucose. Baseline is defined as Day -2.
| mg/dL | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Mean Daily Glucose | -13.85 ± 21.39 | -27.03 ± 24.59 | -34.04 ± 19.43 | -25.89 ± 18.00 | -30.96 ± 25.03 |
Percentage change from baseline to Day 8 in fasting plasma glucose. Baseline is defined as Day -2.
| percentage of fasting plasma glucose | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Fasting Plasma Glucose | -15.88 ± 12.88 | -21.01 ± 6.38 | -25.69 ± 9.88 | -14.21 ± 26.00 | -24.85 ± 8.18 |
Serum insulin measured for on day -2 and day 8 for AUEC0-5 and AUEC0-12. AUEC0-5: The area under the effect concentration-time curve over the time interval 0 to 5. AUEC0-12: The area under the effect concentration-time curve over the time interval 0 to 12.
| µU*h/mL | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| AUEC0-5 (12,9,9,9,9) on day-2 | 134 ± 52.5 | 185 ± 79.2 | 175 ± 70.7 | 137 ± 64.7 | 119 ± 35.9 |
| AUEC0-12 (12,9,9,9,9) on day-2 | 300 ± 111 | 474 ± 149 | 471 ± 143 | 336 ± 161 | 282 ± 41.6 |
| AUEC0-5 (11,9,8,9,9) on day8 | 122 ± 52.0 | 174 ± 80.9 | 180 ± 74.7 | 117 ± 103 | 101 ± 37.2 |
| AUEC0-12 (11,9,7,9,8) on day8 | 288 ± 97.1 | 417 ± 132 | 387 ± 154 | 266 ± 193 | 275 ± 72.4 |
Serum insulin measured for on day -2 and day 8 for Emax0-5, Emax0-12, Emin0-5 and Emin0-12. Emax: Maximum effect (maximum measured concentration of glucose or insulin in plasma) \& Emin: Minimum effect (minimum measured concentration of glucose or insulin in plasma)
| µU/mL | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| Emax,0-5 (12,9,9,9,9) on day-2 | 38.1 ± 17.3 | 55.2 ± 29.9 | 51.2 ± 23.4 | 40.2 ± 19.4 | 35.2 ± 15.5 |
| Emax,0-12 (12,9,9,9,9) on day-2 | 45.4 ± 12.6 | 68.5 ± 25.3 | 72.1 ± 27.7 | 48.7 ± 30.9 | 45.3 ± 11.3 |
| Emin,0-5 (12,9,9,9,9) on day-2 | 10.3 ± 5.46 | 14.1 ± 5.45 | 13.7 ± 4.62 | 9.16 ± 7.59 | 7.86 ± 2.18 |
| Emin,0-12 (12,9,9,9,9) on day-2 | 9.98 ± 4.86 | 14.1 ± 5.45 | 13.5 ± 4.37 | 9.16 ± 7.59 | 7.86 ± 2.18 |
| Emax,0-5 (11,9,8,9,9) on day8 | 35.6 ± 15.6 | 56.0 ± 32.1 | 56.3 ± 25.4 | 36.2 ± 37.3 | 29.6 ± 11.7 |
| Emax,0-12 (11,9,8,9,9) on day8 | 42.6 ± 13.1 | 70.2 ± 26.1 | 68.6 ± 31.1 | 44.4 ± 35.5 | 37.3 ± 8.10 |
| Emin,0-5 (11,9,8,9,9) on day8 | 7.55 ± 3.82 | 8.63 ± 3.39 | 10.7 ± 5.60 | 5.33 ± 3.14 | 3.96 ± 2.79 |
| Emin,0-12 (11,9,8,9,9) on day8 | 7.41 ± 3.90 | 8.53 ± 3.46 | 10.7 ± 5.60 | 5.17 ± 3.19 | 3.96 ± 2.79 |
Collected over day1 to day21. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/12 (0%) | 5/12 (41.7%) |
| Empagliflozin 2.5 mg qd | — | 0/9 (0%) | 6/9 (66.7%) |
| Empagliflozin 10 mg qd | — | 0/9 (0%) | 5/9 (55.6%) |
| Empagliflozin 25 mg qd | — | 0/9 (0%) | 5/9 (55.6%) |
| Empagliflozin 100 mg qd | — | 0/9 (0%) | 3/9 (33.3%) |
| Event | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd |
|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/12 | 0/9 | 2/9 | 1/9 | 0/9 |
| HeadacheNervous system disorders | 1/12 | 0/9 | 1/9 | 2/9 | 0/9 |
| ParaesthesiaNervous system disorders | 0/12 | 2/9 | 0/9 | 0/9 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 2/9 | 0/9 | 0/9 | 0/9 |
| Arthropod stingInjury, poisoning and procedural complications | 0/12 | 0/9 | 0/9 | 2/9 | 0/9 |
| CellulitisInfections and infestations | 0/12 | 0/9 | 1/9 | 0/9 | 0/9 |
| NasopharyngitisInfections and infestations | 0/12 | 0/9 | 0/9 | 1/9 | 1/9 |
| RhinitisInfections and infestations | 0/12 | 0/9 | 0/9 | 1/9 | 0/9 |
| DizzinessNervous system disorders | 0/12 | 1/9 | 1/9 | 0/9 | 0/9 |
| SciaticaNervous system disorders | 0/12 | 1/9 | 1/9 | 0/9 | 0/9 |
Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
| Age, Continuous(years) | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd | Total |
|---|---|---|---|---|---|---|
| Mean | 58.9 ± 6.4 | 53.9 ± 10.9 | 51.8 ± 10.7 | 58.9 ± 8.8 | 60.3 ± 5.6 | 56.9 ± 8.9 |
| Sex: Female, Male(Participants) | Placebo | Empagliflozin 2.5 mg qd | Empagliflozin 10 mg qd | Empagliflozin 25 mg qd | Empagliflozin 100 mg qd | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 2 | 2 | 9 |
| Male | 10 | 7 | 8 | 7 | 7 | 39 |
The record gives a start of Jul 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin